Of note, the treatment of Ezh2/p53-deficient ETP-ALL cells with decitabine resulted in the terminal differentiation of ETP-ALL cells following the reactivation of a set of genes encoding transcriptional regulators of T cell development. Here, EZH2 is linked to acute lymphoblastic leukemia.